The US Food and Drug Administration announced the Global Reliance Disclosure Program (GRDP) on Tuesday, a program under which the agency will share minimally redacted approval packages, including its detailed scientific and regulatory assessments, with drug and biologic sponsors, who can pass them to regulators outside the United States. Foreign authorities can then rely on the FDA’s review decisions rather than conducting their own full evaluations, while keeping sovereignty over their own decisions. Deputy Commissioner Grace Graham called the program “a prime example of America First policies improving public health worldwide.”
The program launched on October 30 with a President’s Emergency Plan for AIDS Relief (PEPFAR) tentative approval for lenacapavir, a drug indicated for HIV prevention and treatment, and is currently available to PEPFAR tentative approvals, excluding tentatively approved abbreviated new drug applications. The FDA intends to expand the program in January 2027 to all novel drug and biologics applications, and to launch a pathway in early 2027 letting applicants request minimally redacted packages for drugs already approved and on the US market. Applicants must ask to participate within 10 calendar days of approval and confirm the package will go to a foreign regulator in support of a marketing application.